Abstract
Most kinase inhibitors reported so far are designed to bind to a highly conserved ATP binding pocket in a competitive manner. In this case, inhibitors targeting the ATP pocket may crossreact with different kinases, as well as with other proteins that bind ATP, and this may cause undesirable side effects that would limit their clinical usefulness. In addition to the kinase selectivity issues, human ether-a-go-go-related gene (hERG) inhibition could be an obstacle to develop a kinase inhibitor as a safe drug. This paper will review the methods employed in the development of selective kinase inhibitors with several successful examples. These include medicinal chemistry efforts to conquer hERG inhibition problems as sometimes seen in kinase inhibitor programs.
Keywords: Protein Kinase, Inhibitors, ATP, human ether-a-go-go-related gene (hERG), drug, T- Type celcium channels Blockers
Mini-Reviews in Medicinal Chemistry
Title: Strategies for the Design of Selective Protein Kinase Inhibitors
Volume: 8 Issue: 12
Author(s): Masaaki Sawa
Affiliation:
Keywords: Protein Kinase, Inhibitors, ATP, human ether-a-go-go-related gene (hERG), drug, T- Type celcium channels Blockers
Abstract: Most kinase inhibitors reported so far are designed to bind to a highly conserved ATP binding pocket in a competitive manner. In this case, inhibitors targeting the ATP pocket may crossreact with different kinases, as well as with other proteins that bind ATP, and this may cause undesirable side effects that would limit their clinical usefulness. In addition to the kinase selectivity issues, human ether-a-go-go-related gene (hERG) inhibition could be an obstacle to develop a kinase inhibitor as a safe drug. This paper will review the methods employed in the development of selective kinase inhibitors with several successful examples. These include medicinal chemistry efforts to conquer hERG inhibition problems as sometimes seen in kinase inhibitor programs.
Export Options
About this article
Cite this article as:
Sawa Masaaki, Strategies for the Design of Selective Protein Kinase Inhibitors, Mini-Reviews in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/138955708786141043
DOI https://dx.doi.org/10.2174/138955708786141043 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Clinical Pharmacology of Trastuzumab
Current Clinical Pharmacology Translational Science: Epistemology and the Investigative Process
Current Genomics Immune Disturbances in Chronic Pain: Cause, Consequence or Both?
Current Immunology Reviews (Discontinued) Mechanisms Leading to COX-2 Expression and COX-2 Induced Tumorigenesis: Topical Therapeutic Strategies Targeting COX-2 Expression and Activity
Anti-Cancer Agents in Medicinal Chemistry Third Generation Radiopharmaceuticals for Imaging and Targeted Therapy
Current Pharmaceutical Analysis Evaluation of Novel Radioiodinated C7-substituted Δ6,7 – estradiol Derivatives for Molecular Recognition of ER-Positive Breast Tumours
Current Radiopharmaceuticals The Proteasome in Health and Disease
Current Pharmaceutical Design Anti-Epidermal Growth Factor Receptor Antibodies in the Treatment of Metastatic Colorectal Cancer
Recent Patents on Anti-Cancer Drug Discovery Regulation of Cell Growth by Estrogen Signaling and Potential Targets in Thyroid Cancer
Current Cancer Drug Targets Highly Sensitive Chitosan and ZrO2 Nanoparticles-Based Electrochemical Sensor for 8-Hydroxy-2’-deoxyguanosine Determination
Current Analytical Chemistry Chemical Biology: Past, Present and Future
Current Chemical Biology Obesity: An Emerging Importance of Progenitors
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Small Molecules ATP-Competitive Inhibitors of FLT3: A Chemical Overview
Current Medicinal Chemistry Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine The Zinc Metallopeptidase Family: New Faces, New Functions
Protein & Peptide Letters Nanoparticles for Triggering and Regulation of Immune Response of Vaccines: Perspective and Prospective
Current Pharmaceutical Biotechnology Gene Therapy of Cancer Based on Interleukin 12
Current Gene Therapy Role of Antioxidants for the Treatment of Cardiovascular Diseases: Challenges and Opportunities
Current Pharmaceutical Design Synchrotron Radiation in Life Sciences
Protein & Peptide Letters mTOR Inhibitors: Facing New Challenges Ahead
Current Medicinal Chemistry